Drug Trial Radar · NCT04142424
A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
Last checked: Nov 19, 2026Latest source record: Nov 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Oct 28, 2019
Primary completion
Nov 12, 2021
Study completion Nov 12, 2021
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Oct 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This Phase 1, first-in-human (FiH), single-ascending-dose (SAD) study, will assess the safety and tolerability and characterize the pharmacokinetics (PK) of AZD2693, following subcutaneous (SC) SAD administration of AZD2693 in male and female subjects of non-childbearing potential in overweight but otherwise healthy subjects, and healthy Chinese and Japanese subjects.
Conditions
- Metabolic Disorders
- Non-alcoholic Steatohepatitis
Interventions
AZD2693Drug
Subjects will receive SC injection of AZD2693 as per the arms they are randomized.
PlaceboDrug
Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects experiencing adverse events and serious adverse eventsTime frame: From baseline (Day 1) until Day 112 (Week 16, Final follow-up)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.